Fundraising Fox
/Companies
Sign in

Certara

NASDAQ: CERT

Radnor, US · Founded 2017 · Delaware corporation · 1,490 employees on LinkedIn · 2 known investors

Find your way into Certara

Sign up to see every warm intro you have to Certara

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Certara team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Certara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases. It serves pharmaceutical and biotech organizations seeking to make data-driven decisions and streamline regulatory submissions.

AI & Machine LearningBiotechHealthtechSaaS

Founders & leadership

DCDaniel Corcoran
Daniel CorcoranSenior Vice President and General CounselDaniel Corcoran is SVP and General Counsel at Certara, a biosimulation and regulatory services company. He previously practiced corporate law at Sullivan & Cromwell in New York and Frankfurt, and has served as General Counsel at multiple private and public companies in AI and SaaS sectors.
WFWilliam Feehery
William FeeheryCEOWilliam Feehery is CEO and Director of Certara, a company providing biosimulation software, modeling, and regulatory services to support pharmaceutical and biotech organizations throughout drug discovery and development.
JWJieun W. Choe
Jieun W. ChoeChief Strategy and Marketing Officer2020–2022Chief Strategy & Marketing Officer at Certara, which provides biosimulation software and regulatory services for pharmaceutical drug development. Experienced executive who has led strategy and operations at venture and private-equity-backed growth-stage technology companies.
RMRichard M. Traynor
Richard M. TraynorConsultantRichard M. Traynor is Senior Vice President and General Counsel at Certara. He brings over 25 years of legal and executive experience in technology and life sciences at both public and private companies, with expertise spanning securities law, M&A, regulatory compliance, and data privacy.
CR
Craig R. RaynerPresident, Integrated Drug Development
JEJustin Edge
Justin EdgePresident, Regulatory & Access2019–2022Justin Edge is President of Regulatory and Access at Certara, a provider of biosimulation software and regulatory services for pharmaceutical and biotech companies. He brings experience in regulatory and market access functions across life sciences, with involvement in multiple M&A and corporate transactions.
NDNicolette D. Sherman
Nicolette D. ShermanChief Human Resources Officer2021–2024Nicolette D. Sherman is Chief Human Resources Officer at Certara, a biosimulation and regulatory services company serving the pharmaceutical and biotech sectors. She has held senior HR leadership roles at Oyster Point Pharma, Sanofi, and Schering-Plough, with experience in talent management, organizational development, and workforce planning.
JRJon Resnick
Jon ResnickCEOCEO of Certara, a biosimulation software and regulatory services provider for drug development. Healthcare executive with experience leading global teams and building businesses focused on data-driven solutions in life sciences.
JEJohn E. Gallagher III
John E. Gallagher IIISenior Vice President and Chief Financial Officer
RARobert A. Aspbury
Robert A. AspburyPresident, Certara Predictive Technologies
LELeif E. Pedersen
Leif E. PedersenPresident, Chief Commercial OfficerLeif E. Pedersen is President and Chief Commercial Officer at Certara. With over 35 years in software technology, he has held leadership roles in sales, R&D, product management, and marketing at companies including SymphonyAI, Dassault Systemes, Accelrys Software, Siemens, UGS, Oracle, and Computer Associates.
AKAdrian K. McKemey
Adrian K. McKemeyPresidentAdrian McKemey holds a Ph.D. in High Energy Nuclear Particle Physics from the University of London and has spent over 25 years in drug development and life sciences strategy, including roles as a Principal at Boston Consulting Group, head of R&D Strategy Solutions at Quintiles, and enterprise transformation leader at IQVIA, before becoming President of Certara Drug Development Solutions.

Investors · 2

Iaso VenturesinferredCambridgevia John Reynders · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$14.3M disclosed across 2 of 4 rounds · 2021–2026

▶$8.6MraisedApr 2026 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Rona AnhaltExecutive Officer
  • Cynthia CollinsDirector
  • Eran BroshyDirector
  • Matthew WalshDirector
  • Stephen McLeanDirector
  • James CashmanDirector
  • David SpaightDirector
  • John Gallagher IIIExecutive Officer
  • Nancy KilleferDirector
  • Daniel CorcoranExecutive Officer
  • Arjun BediDirector
  • Rosemary CraneDirector
  • Robert AspburyExecutive Officer
  • John ReyndersDirector
  • Leif PedersenExecutive Officer
  • Adrian McKemeyExecutive Officer
  • Jon ResnickExecutive Officer, Director
Amount sold
$8.6M
First sale
Apr 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.7MraisedMar 2025 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John Gallagher IIIExecutive Officer
  • Adrian McKemeyExecutive Officer
  • Rona AnhaltExecutive Officer
  • Cynthia CollinsDirector
  • Daniel CorcoranExecutive Officer
  • John ReyndersDirector
  • Stephen McLeanDirector
  • Matthew WalshDirector
  • Robert AspburyExecutive Officer
  • Eran BroshyDirector
  • Leif PedersenExecutive Officer
  • William FeeheryExecutive Officer, Director
  • David SpaightDirector
  • Rosemary CraneDirector
  • James CashmanDirector
  • Nancy KilleferDirector
Amount sold
$5.7M
First sale
Mar 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedMar 2024 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cynthia CollinsDirector
  • Patrick SmithExecutive Officer
  • Rosemary CraneDirector
  • Nancy KilleferDirector
  • Nicolette ShermanExecutive Officer
  • Eran BroshyDirector
  • Matthew WalshDirector
  • Stephen McLeanDirector
  • John Gallagher IIIExecutive Officer
  • Robert AspburyExecutive Officer
  • David SpaightDirector
  • William FeeheryExecutive Officer, Director
  • Leif PedersenExecutive Officer
  • James Cashman IIIDirector
  • Richard TraynorExecutive Officer
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedSep 2021 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jieun W. ChoeExecutive Officer
  • Richard M. TraynorExecutive Officer
  • Craig R. RaynerExecutive Officer
  • Nancy KilleferDirector
  • Carol G. GallagherDirector
  • Eric C. LiuDirector
  • Robert AspburyExecutive Officer
  • Justin EdgeExecutive Officer
  • Leif E. PedersenExecutive Officer
  • Ethan WaxmanDirector
  • Nicolette D. ShermanExecutive Officer
  • Cynthia CollinsDirector
  • Michael Andrew SchemickExecutive Officer
  • Sherilyn S. McCoyExecutive Officer
  • Mason P. SlaineDirector
  • Matthew WalshDirector
  • James E. Cashman IIIDirector
  • Stephen M. McLeanDirector
  • William F. FeeheryExecutive Officer, Director
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Certara do?
Certara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases. It serves pharmaceutical and biotech organizations seeking to make data-driven decisions and streamline regulatory submissions.
Who are Certara's investors?
Certara's investors include Arsenal, Iaso Ventures.
How much funding has Certara raised?
Certara has disclosed $14.3M raised across 2 of its 4 known rounds.
Where is Certara headquartered?
Certara is headquartered in Radnor, US.